Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches Within Tumor Cells: A Future Perspective of Cancer Management

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Apr 28

PMID 37108214

Authors

Khaled S Allemailem

Saleh A Almatroodi

Ahmad Almatroudi

Faris Alrumaihi

Waleed Al Abdulmonem

Wafa Abdullah I Al-Megrin

Adel Nasser Aljamaan

Arshad Husain Rahmani

Amjad Ali Khan

Affiliations

Soon will be listed here.

Abstract

The innovative advances in transforming clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9) into different variants have taken the art of genome-editing specificity to new heights. Allosteric modulation of Cas9-targeting specificity by sgRNA sequence alterations and protospacer adjacent motif (PAM) modifications have been a good lesson to learn about specificity and activity scores in different Cas9 variants. Some of the high-fidelity Cas9 variants have been ranked as Sniper-Cas9, eSpCas9 (1.1), SpCas9-HF1, HypaCas9, xCas9, and evoCas9. However, the selection of an ideal Cas9 variant for a given target sequence remains a challenging task. A safe and efficient delivery system for the CRISPR/Cas9 complex at tumor target sites faces considerable challenges, and nanotechnology-based stimuli-responsive delivery approaches have significantly contributed to cancer management. Recent innovations in nanoformulation design, such as pH, glutathione (GSH), photo, thermal, and magnetic responsive systems, have modernized the art of CRISPR/Cas9 delivery approaches. These nanoformulations possess enhanced cellular internalization, endosomal membrane disruption/bypass, and controlled release. In this review, we aim to elaborate on different CRISPR/Cas9 variants and advances in stimuli-responsive nanoformulations for the specific delivery of this endonuclease system. Furthermore, the critical constraints of this endonuclease system on clinical translations towards the management of cancer and prospects are described.

Citing Articles

CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations.

Lee H, Rho W, Kim Y, Chang H, Jun B Molecules. 2025; 30(3).

PMID: 39942646 PMC: 11820414. DOI: 10.3390/molecules30030542.

Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology.

Youssef E, Fletcher B, Palmer D Front Med (Lausanne). 2025; 11:1527600.

PMID: 39871848 PMC: 11769984. DOI: 10.3389/fmed.2024.1527600.

Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine.

Azeez S, Hamad R, Hamad B, Shekha M, Bergsten P Front Genome Ed. 2024; 6:1509924.

PMID: 39726634 PMC: 11669675. DOI: 10.3389/fgeed.2024.1509924.

Unlocking Fungal Potential: The CRISPR-Cas System as a Strategy for Secondary Metabolite Discovery.

Leal K, Rojas E, Madariaga D, Contreras M, Nunez-Montero K, Barrientos L J Fungi (Basel). 2024; 10(11).

PMID: 39590667 PMC: 11595728. DOI: 10.3390/jof10110748.

Nanomedicine for cancer patient-centered care.

Sorrentino C, Ciummo S, Fieni C, Di Carlo E MedComm (2020). 2024; 5(11):e767.

PMID: 39434967 PMC: 11491554. DOI: 10.1002/mco2.767.

References

Tang Q, Liu J, Jiang Y, Zhang M, Mao L, Wang M . Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid. ACS Appl Mater Interfaces. 2019; 11(50):46585-46590. DOI: 10.1021/acsami.9b17749. View

Yin H, Sun L, Pu Y, Yu J, Feng W, Dong C . Ultrasound-Controlled CRISPR/Cas9 System Augments Sonodynamic Therapy of Hepatocellular Carcinoma. ACS Cent Sci. 2021; 7(12):2049-2062. PMC: 8704033. DOI: 10.1021/acscentsci.1c01143. View

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

Oakes B, Nadler D, Flamholz A, Fellmann C, Staahl B, Doudna J . Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch. Nat Biotechnol. 2016; 34(6):646-51. PMC: 4900928. DOI: 10.1038/nbt.3528. View

Pattanayak V, Lin S, Guilinger J, Ma E, Doudna J, Liu D . High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 2013; 31(9):839-43. PMC: 3782611. DOI: 10.1038/nbt.2673. View

Naguib Y, Cui Z . Nanomedicine: the promise and challenges in cancer chemotherapy. Adv Exp Med Biol. 2014; 811:207-33. DOI: 10.1007/978-94-017-8739-0_11. View

Nihongaki Y, Otabe T, Sato M . Emerging Approaches for Spatiotemporal Control of Targeted Genome with Inducible CRISPR-Cas9. Anal Chem. 2017; 90(1):429-439. DOI: 10.1021/acs.analchem.7b04757. View

Wang M, Glass Z, Xu Q . Non-viral delivery of genome-editing nucleases for gene therapy. Gene Ther. 2016; 24(3):144-150. DOI: 10.1038/gt.2016.72. View

Aubrey B, Kelly G, Kueh A, Brennan M, OConnor L, Milla L . An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015; 10(8):1422-32. DOI: 10.1016/j.celrep.2015.02.002. View

10.

Ishino Y, Krupovic M, Forterre P . History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology. J Bacteriol. 2018; 200(7). PMC: 5847661. DOI: 10.1128/JB.00580-17. View

11.

Javaid N, Pham T, Choi S . Functional Comparison between VP64-dCas9-VP64 and dCas9-VP192 CRISPR Activators in Human Embryonic Kidney Cells. Int J Mol Sci. 2021; 22(1). PMC: 7795359. DOI: 10.3390/ijms22010397. View

12.

Shankar S, Sreekumar A, Prasad D, Das A, Pillai M . Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design. Cancer Cell Int. 2018; 18:169. PMC: 6198504. DOI: 10.1186/s12935-018-0666-0. View

13.

Bharathkumar N, Sunil A, Meera P, Aksah S, Kannan M, Saravanan K . CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review. Mol Biotechnol. 2021; 64(4):355-372. PMC: 8571677. DOI: 10.1007/s12033-021-00422-8. View

14.

Nunez J, Harrington L, Doudna J . Chemical and Biophysical Modulation of Cas9 for Tunable Genome Engineering. ACS Chem Biol. 2016; 11(3):681-8. DOI: 10.1021/acschembio.5b01019. View

15.

Kleinstiver B, Pattanayak V, Prew M, Tsai S, Nguyen N, Zheng Z . High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016; 529(7587):490-5. PMC: 4851738. DOI: 10.1038/nature16526. View

16.

Kim D, Luk K, Wolfe S, Kim J . Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases. Annu Rev Biochem. 2019; 88:191-220. DOI: 10.1146/annurev-biochem-013118-111730. View

17.

Chen X, Chen Y, Xin H, Wan T, Ping Y . Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing. Proc Natl Acad Sci U S A. 2020; 117(5):2395-2405. PMC: 7007568. DOI: 10.1073/pnas.1912220117. View

18.

Rauch B, Silvis M, Hultquist J, Waters C, McGregor M, Krogan N . Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. Cell. 2017; 168(1-2):150-158.e10. PMC: 5235966. DOI: 10.1016/j.cell.2016.12.009. View

19.

Liu J, Chang J, Jiang Y, Meng X, Sun T, Mao L . Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles. Adv Mater. 2019; 31(33):e1902575. PMC: 6732788. DOI: 10.1002/adma.201902575. View

20.

Chen G, Abdeen A, Wang Y, Shahi P, Robertson S, Xie R . A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol. 2019; 14(10):974-980. PMC: 6778035. DOI: 10.1038/s41565-019-0539-2. View